Skip to main content

Table 1 Log odds ratios (95% CIs) for the treatment effect β and the regression coefficients γ calculated using BPSA and PSA.

From: Covariate balance in a Bayesian propensity score analysis of beta blocker therapy in heart failure patients

Description Parameter Log Odds Ratio (95% Interval Estimate)
   BPSA PSA
Beta blocker β -0.21 (-0.37, -0.05) -0.31 (-0.46, -0.15)
Demographics    
   Female Sex γ 1 0.17 (0.06, 0.29) 0.12 (-0.01, 0.25)
   Age    
< 65 (reference) . 0.00 0.00
65 - 74 γ 2 -0.19 (-0.32, -0.04) -0.09 (-0.3, 0.12)
75 - 84 γ 3 -0.40 (-0.56, -0.24) -0.21 (-0.41, 0.00)
> 85 γ 4 -0.71 (-0.94, -0.46) -0.37 (-0.59, -0.14)
Comorbid conditions    
   Cerebrovascular dis. γ 5 -0.11 (-0.67, 0.44) 0.25 (-0.46, 0.96)
   COPD γ 6 -0.32 (-0.60, -0.06) -0.89 (-1.30, -0.49)
   Hyponatremia γ 7 -0.02 (-0.26, 0.21) 0.03 (-0.33, 0.39)
   Metastatic disorder γ 8 -1.42 (-2.33, -0.56) -0.40 (-1.37, 0.57)
   Renal disease γ 9 -0.17 (-0.32, 0.01) 0.38 (0.15, 0.62)
   Ventricular arrhythmia γ 10 -0.12 (-0.63, 0.44) 0.12 (-0.62, 0.86)
   Liver disease γ 11 -0.52 (-1.03, -0.08) -1.11 (-2.04, -0.19)
   Malignancy γ 12 -0.78 (-1.19, -0.34) -0.06 (-0.57, 0.45)
   Shock γ 13 -0.06 (-0.56, 0.39) -0.12 (-0.83, 0.58)
Hospitalization    
   Transferred γ 14 -0.41 (-0.58, -0.25) -0.01 (-0.22, 0.20)
   Stay (10 day intvs.) γ 15 -0.13 (-0.18, -0.09) -0.05 (-0.11, 0.01)
Heart failure medications    
   Digoxin γ 16 -0.02 (-0.11, 0.07) 0.00 (-0.14, 0.13)
   Diuretic γ 17 0.28 (0.09, 0.48) 0.72 (0.54, 0.90)
   CCB γ 18 0.22 (0.08, 0.35) 0.27 (0.10, 0.44)
   ACE inhibitor γ 19 0.29 (0.11, 0.45) 0.61 (0.47, 0.76)
   ARB γ 20 0.18 (-0.06, 0.46) 0.53 (0.19, 0.87)
   Statin γ 21 0.91 (0.65, 1.24) 0.94 (0.76, 1.12)